April 1, 1994Coronary Artery Disease
Antiplatelet and antithrombin therapy
Why the study?
Do antiplatelet and antithrombin agents as adjunctive therapy to thrombolysis improve outcomes in patients with acute myocardial infarction?
Population
Patients with acute myocardial infarction receiving thrombolytic therapy
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports antiplatelet therapy to reduce death/reinfarction after thrombolysis in AMI; leaves open heparin's incremental value with full-dose aspirin.
Structured PICO
Do antiplatelet and antithrombin agents as adjunctive therapy to thrombolysis improve outcomes in patients with acute myocardial infarction?
P
Population
Patients with acute myocardial infarction receiving thrombolytic therapy
I
Intervention
Antiplatelet and antithrombin agents as adjunctive therapy to thrombolysis
This review highlights the established benefit of adjunctive antiplatelet therapy in preventing death and reinfarction after thrombolysis for acute myocardial infarction, while noting limited added benefit from heparin when combined with full-dose aspirin.
Cite This Study
Fernández‐Ortíz et al. (1994) studied this question.